<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9015</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cancerología]]></journal-title>
<abbrev-journal-title><![CDATA[rev.colomb.cancerol.]]></abbrev-journal-title>
<issn>0123-9015</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cancerología E.S.E.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-90152017000200086</article-id>
<article-id pub-id-type="doi">10.1016/j.rccan.2017.04.001</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Resultados del tratamiento de osteosarcoma convencional de alto grado en niños y adolescentes: análisis de supervivencia de una cohorte tratada sin metotrexato]]></article-title>
<article-title xml:lang="en"><![CDATA[Treatment outcomes in conventional high-grade osteosarcoma in children and adolescents: An analysis of survival of a cohort treated without methotrexate]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[Amaranto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[Camilo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gamboa]]></surname>
<given-names><![CDATA[Óscar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[Diego]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escandón]]></surname>
<given-names><![CDATA[Santiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Terselich]]></surname>
<given-names><![CDATA[Greti]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cancerología Clínica de Oncología Pediátrica ]]></institution>
<addr-line><![CDATA[Bogotá D. C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Cancerología Clínica de Ortopedia Oncológica ]]></institution>
<addr-line><![CDATA[Bogotá D. C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Cancerología ubdirección de investigación, vigilancia epidemiológica, promoción y prevención ]]></institution>
<addr-line><![CDATA[Bogotá D. C]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>21</volume>
<numero>2</numero>
<fpage>86</fpage>
<lpage>94</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-90152017000200086&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-90152017000200086&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-90152017000200086&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Reportar la supervivencia global, libre de evento, la respuesta histológica a quimioterapia neoadyuvante y los resultados de la cirugía de preservación de la extremidad en pacientes con osteosarcoma convencional tratados sin altas dosis de metotrexato en el Instituto Nacional de Cancerología de Colombia.  Pacientes y métodos:  una cohorte de pacientes menores de 21 años de edad con diagnóstico de osteosarcoma convencional, con o sin metástasis, fueron tratados con quimioterapia preoperatoria por doce semanas; seguidos de cirugía de control local en la semana 15 y tres ciclos de quimioterapia posoperatoria. En el tratamiento se administraron cuatro medicamentos (ifosfamida, doxorrubicina, cisplatino y etopósido) y no se incluyó el uso de metotrexato. La supervivencia global y libre de evento fue calculada por el método de Kaplan-Meier. Se realizó análisis multivariable para predictores de supervivencia mediante el modelo de riesgos proporcionales de Cox. Los análisis estadísticos se realizaron para &#945; 0,05.  Resultados:  Entre enero de 1997 y diciembre de 2007 ingresaron 122 pacientes con osteosarcoma convencional, para una mediana de seguimiento de 25,4 meses (rango 1,13 a 169). La edad promedio fue 13,7 años (DE: 2,9) y de los procedimientos quirúrgicos la cirugía de salvamento correspondió al 52% y la cirugía ablativa al 38%. La supervivencia global y libre de evento fue mayor en los buenos respondedores a quimioterapia que en malos respondedores (HR = 4,33; IC 95% 1,77-10,58)) y (HR = 2,90; IC 95% 1,60-5,27). La supervivencia global y libre de evento fue diferente entre los pacientes con y sin metástasis al diagnóstico (HR = 2,13; IC 95% 0,97-4,72) y(HR = 2,07; (IC 95% 1,10 - 3,90).  Conclusión:  El osteosarcoma puede ser tratado con quimioterapia sin altas dosis de metotrexato logrando supervivencia moderadamente efectiva y comparable con la de países desarrollados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To report event-free overall survival rates and histological response results for neoadjuvant chemotherapy and limb-salvage surgery in conventional osteosarcoma patients treated without high methotrexate doses in the National Cancer Institute of Colombia.  Patients and Methods:  A cohort of under 21-year old patients diagnosed with conventional osteosarcoma, with or without metastasis, underwent preoperative chemotherapy for twelve weeks, followed by local control surgery in week 15, and three postoperative chemotherapy cycles. Treatment did not include methotrexate. Four drugs were administered: ifosfamide, doxorubicin, cisplatin, and etoposide. The Kaplan-Meier method was used to calculate overall survival and event-free rates. A multivariate analysis of survival predictors was carried out with the Cox proportional hazards method. Statistical analysis was based on an &#945; of 0.05.  Results:  From January 1997 to December 2007, a total of l22 conventional osteosarcoma patients received treatment, with a median follow-up of 24.4 months (range 1.13 to 169). The mean patient age was 13.7 years (SD ±2.9 yrs). Limb-salvage surgery was performed in 52% and ablative surgery in 38%. Overall survival and event-free rates were higher in the good responders to chemotherapy than in the poor responders: (HR = 4.33; 95% CI; 1.77-10.58) and (HR = 2.90; 95% CI; 1.60-5.27. The overall survival and event-free rates were different between patients with and without metastasis at diagnosis: (HR = 2.13; 95% CI; 0.97-4.72) and (HR = 2.07; (95% CI; 1.10-3.90.  Conclusion:  Osteosarcoma can be treated with chemotherapy without high methotrexate doses to achieve moderately effective survival rates comparable with those in developed countries.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Osteosarcoma]]></kwd>
<kwd lng="es"><![CDATA[Quimioterapia]]></kwd>
<kwd lng="es"><![CDATA[Supervivencia]]></kwd>
<kwd lng="es"><![CDATA[Colombia]]></kwd>
<kwd lng="en"><![CDATA[Osteosarcoma]]></kwd>
<kwd lng="en"><![CDATA[Chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[Survival]]></kwd>
<kwd lng="en"><![CDATA[Colombia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheurer]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Bondy]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Gurney]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of childhood cancer]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pizzo]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Poplack]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<source><![CDATA[Principles and Practices of Pediatric Oncology]]></source>
<year>2011</year>
<edition>Sixth</edition>
<page-range>2-16</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lip-pinccott Williams and Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Janeway]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Gorlick]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bernstein]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteosarcoma]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Orkin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Look]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Lux]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ginsburg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nathan]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncology of infancy and childhood]]></source>
<year>2009</year>
<page-range>871-910</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Saunders Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Collazos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carrascal]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Cáncer Infantil en Cali, Colombia, 1994-2003]]></source>
<year>2009</year>
<publisher-name><![CDATA[Registro Poblacional de Cáncer de Cali]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorlick]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bielack]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Teot]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Randall]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[steosar-coma. Biology, diagnosis, treatment and remaining challenges]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pizzo]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Poplack]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<source><![CDATA[Principles and Practices of Pediatric Oncology]]></source>
<year>2011</year>
<edition>Sixth</edition>
<page-range>1015-44</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lippinccott Williams and Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bone tumors osteosarcoma and Ewing&#8217;s sarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heare]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hensley]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Dell&#8217;Orfano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Current Opinion in Pediatrics]]></source>
<year>2009</year>
<volume>21</volume>
<page-range>365-72</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sanmaneechai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beattie Jr]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marcove]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1975</year>
<volume>35</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>936-45</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma pre-surgical treatment of primary tumor and of overt pulmonary metastases]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaffe]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Frei 3rd]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Traggis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Watts]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1977</year>
<volume>39</volume>
<page-range>45-50</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[High-dose methotrexate and citrovorum factor rescue and Adriamycin in childhood osteogenic sarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Suwansirikui]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Beattie Jr]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1974</year>
<volume>33</volume>
<page-range>1151-63</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma Analysis of the literature]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Delepine]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Delepine]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bacci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Desbois J-C]]></surname>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1996</year>
<volume>78</volume>
<page-range>2127-35</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Frontline Treatment of Localized Osteosarcoma Without Methotrexate Results of the St. Jude Children&amp;apos;s Research Hospital OS99 Trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daw]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Neel]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Billups]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkins]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>2011</year>
<volume>117</volume>
<page-range>2770-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Preoperative chemotherapy for osteogenic sarcoma selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Caparros]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Huvos]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Kosloff]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[NirenbergA]]></surname>
</name>
<name>
<surname><![CDATA[Cacavio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1982</year>
<volume>49</volume>
<page-range>1221-30</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Carboplatin/ifosfamide window therapy for osteosar-coma results of the St Jude Children&#8217;s Research Hospital OS-91 trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Pratt]]></surname>
<given-names><![CDATA[CHB]]></given-names>
</name>
<name>
<surname><![CDATA[Poquette]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Parham]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Marina]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2001</year>
<volume>19</volume>
<page-range>171-82</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Osteosarcoma A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyers]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Krailo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kleinerman]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Betcher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bernstein]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2005</year>
<volume>23</volume>
<page-range>2004-11</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crews]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[LiuT]]></surname>
</name>
<name>
<surname><![CDATA[Rodriguez-GalindoC]]></surname>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Panetta]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>2004</year>
<volume>100</volume>
<page-range>1724-33</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of newly diagnosed high grade osteosarcoma (OS) with ifosfamida (IFOS), adriamycin (ADR) and cisplatin (CDP) without high dose methotrexate [abstract]]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epelman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Seibel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Melaragno]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Pediatr Oncol]]></source>
<year>1996</year>
<volume>27</volume>
<page-range>226</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of plasma pharmacokinetics to predict and preventmet hotre-xate toxicity]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stoller]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Hande]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Chabner]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>1977</year>
<volume>297</volume>
<page-range>630-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Severe acute toxicity associated with high-dose methotrexate (MTX) therapy use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estève]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Devictor-Pierre]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Galy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[André]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Coze]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Laca-relle]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2007</year>
<volume>63</volume>
<page-range>39-42</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Survival from high-grade localised extremity osteosarcoma combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whelan]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Jinks]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[McTiernan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sydes]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Hook]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Trani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Oncol]]></source>
<year>2012</year>
<volume>23</volume>
<page-range>1607-16</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A Comparison of Two Short Intensive Adjuvant Chemotherapy Regimens in Operable Osteosarcoma of Limbs in Children and Young Adults]]></article-title>
<collab>The First Study of the European Osteosarcoma IntergroupBram-well VH.Burgers M.Sneath R.Souhami R.Van Oosterom AT.Voüte PA</collab>
<source><![CDATA[J Clin Oncol]]></source>
<year>1992</year>
<volume>10</volume>
<page-range>1579-91</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chemotherapyfor osteosarcoma without high-dose methotrexate a 12 year follow-up on 53 patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tunn]]></surname>
<given-names><![CDATA[PU]]></given-names>
</name>
<name>
<surname><![CDATA[Reichardt]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Onkologie]]></source>
<year>2007</year>
<volume>30</volume>
<page-range>228-32</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Osteosarcoma in patients younger than 12 years old sithout metastases have similar prognosis as adolescent and young adults]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eleutério]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Senerchia]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Da Costa]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Lustosa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Calheiros]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2015</year>
<volume>62</volume>
<page-range>1209-13</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fifteen Years&amp;apos; Experience of the Brazilian Osteosarcoma Treatment Group (BOTG) A Contribution from an Emerging Country]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petrilli]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Brunetto]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Cypriano Mdos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferraro]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Donato Macedo]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Senerchia]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Adolesc Young Adult Oncol]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>145-52</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[XC]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Oncol]]></source>
<year>2014</year>
<volume>21</volume>
<page-range>e678-84</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities 27 year experience at Rizzoli Institute, Italy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bacci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Longhi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fagioli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Briccoli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Versari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Picci]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Cancer]]></source>
<year>2005</year>
<volume>41</volume>
<page-range>2836-45</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Weekly highdose methotrexate and doxorubicin for osteosarcoma; the Dana Farber Cancer Institute/the Childrens Hospital-study III]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goorin]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Perez-Atayde]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gebhardt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkinson]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Delorey]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>1987</year>
<volume>5</volume>
<page-range>1178-84</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of nonmetastatic osteosarcoma of the extremity with pre-operative and postoperative chemotherapy a report from the Children&amp;apos;s. Cancer. Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Provisor]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ettinger]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nachman]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Krailo]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Makley]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Yunis]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>1997</year>
<volume>15</volume>
<page-range>76-84</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Predictive factors for local recurrence in osteosarcoma 540 patients with extremety tumors followed for minimum 2.5 years after neoadjuvant chemotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bacci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mercuri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bertoni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Picci]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Manfrini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Acta Orthop Scand]]></source>
<year>1998</year>
<volume>69</volume>
<page-range>230-6</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smeland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alvegard]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Wiklund]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wiebe]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Björk]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Cancer]]></source>
<year>2003</year>
<volume>39</volume>
<page-range>488-94</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<collab>Southwest Oncology Group study 9139</collab>
<article-title xml:lang=""><![CDATA[Adjuvant therapy of osteosarcoma-A Phase II trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zalupski]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Rankin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Muler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lanier]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>2004</year>
<volume>100</volume>
<page-range>818-25</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
